Explore Our Novel Cyclobutane Derivatives

Our Unique Building Blocks to Perform Far and Wide
14 December 2020
Oleg Lukin
Senior Research Scientist

Сyclobutanes are heavily exploited in organic synthesis as subunits for natural product preparation, ring-opening, and ring-contraction reactions.1 In medicinal chemistry, the introduction of a cyclobutane fragment is often used to achieve a conformational restriction.2 Unlike a double bond or a cyclopropane unit, the cyclobutane ring does not disturb the electronic properties and, consequently, the reactivity of a biologically active molecule.

Although cyclobutane derivatives have been less commonly exploited in drug discovery to date, there are five marketed and several experimental drugs containing the cyclobutane ring.3 For example, Boceprevir 1, a protease inhibitor used as a treatment for hepatitis C and semisynthetic analgesic Nalbuphine 2 shown in Figure 1 are classical cyclobutane-containing medications. Carboplatin 3, a drug used for treatment of different types of cancer, was approved and commercialized in 2011. A selective inhibitor of alcohol dehydrogenase 1A 4 is an experimental drug. Recent evaluations of biological activity in a series of thiazole-based agents showed that the introduction of a cyclobutane fragment into the thiazole ring led to significantly improved antifungal and antibacterial activities in the сompound 5 (Figure 1).4

Along with drug discovery, the cyclobutane derivatives have found important applications in materials science, e.g., to produce stress-responsive polymers,6 and supramolecular chemistry.6

Some biologically active compounds containing the cyclobutane moiety

Figure 1. Marketed drugs and some other biologically active compounds containing the cyclobutane moiety

The representative set of cyclobutane derivatives available from Life Chemicals is listed below. To explore the full data set, please send your request to orders@lifechemicals.com.

Representative cyclobutane derivatives available from Life Chemicals


  1. (a) Wang, M.; Lu, P. Org. Chem. Front. 2018, 5, 254-259. (b) Namyslo, J. C.; Kaufmann, D. E. Chem. Rev. 2003, 103, 1485-1537.
  2. Radchenko, D. S.; Pavlenko, S. O.; Grygorenko, O. O.; Volochnyuk, D. M.; Shishkina, S. V.; Shishkin, O. V.; Komarov, I. V. J. Org. Chem. 2010, 75, 5941–5952.
  3. www.drugbank.ca; accessed on September 2019.
  4. Cukurovali, A.; Yilmaz, I.; Gur, S.; Kazaz, C. Eur. J. Med. Chem. 2006, 41, 201–207.
  5. Kean, Z. S.; Niu, Z.; Hewage, G. B.; Rheingold, A. L.; Craig, S. L. J. Am. Chem. Soc. 2013, 135, 13598−13604.
  6. Rua, F.; Boussert, S.: Parella, T.; Dıez-Perez, I.; Branchadell, V.; Giralt, E.; Ortuno, R. M. Org. Lett. 2007, 9, 3643-3645.
14 December 2020, 17:28 Oleg Lukin Building Blocks

Comments ()

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept